Otsuka Seeks Accelerated Approval for Sibeprenlimab in IgA Nephropathy Following Positive Phase III Interim Results

Otsuka, sibeprenlimab, IgA nephropathy, Phase III trial, accelerated approval, FDA, kidney disease, autoimmune disease, APRIL antibody.

Purespring Therapeutics Secures £80M ($105M) Series B Funding to Advance IgAN Gene Therapy into Clinical Trials

Purespring Therapeutics, IgAN gene therapy, kidney disease, Series B funding, clinical trials, AAV gene therapy, podocytes, nephrotic syndrome, glomerular kidney disease.

Novartis and Versant Ventures Launch Borealis Biosciences to Develop RNA Medicines for Kidney Diseases

Borealis Biosciences, Novartis, Versant Ventures, RNA medicines, kidney diseases, xRNA technology, biotechnology, startup, kidney research, RNA therapeutics.